Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. [PDF]
, 2020 Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged ...
Balistreri, William F +20 more
core
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection [PDF]
, 2018 Hepatitis C Virus (HCV) infection is major health problem worldwide, with 150 million infected people according to recent epidemiologic estimations.
Gragnani L, Monti M, Zignego AL
core +1 more source
Innate Immunity in the immunopathogenesis of chronic viral infection [PDF]
, 2016 Natural killer (NK) cells have a key role in control and clearance of viral infections. To carry out this function NK cells are capable of recognising infected cells and responding with induction of apoptosis in these cells, and production of pro ...
Malone, David
core +1 more source
Nuevos fármacos antivirales de acción directa en una población atendida por una unidad de enfermedades infecciosas. Estudio descriptivo [PDF]
, 2017 La hepatitis C es una enfermedad infecciosa que afecta principalmente al hígado y está causada por un virus RNA de cadena positiva perteneciente a la familia Flaviviridae, género Hepacivirus, del que se conocen 7 genotipos, el último descrito ...
Gutiérrez Vélez, Rebeca
core
Annals of HepatologyIntroduction and Objectives: Currently, HCV treatment options during pregnancy are not well-defined. Typical clinical practice is to refer and link pregnant women for treatment after pregnancy and breastfeeding; however, in practice, very few have ...
Maria Teresa Guzmán Terrones +3 more
doaj +1 more source
Characterization of resistance associated variants associated to NS5A inhibitors in patients with chronic hepatitis C [PDF]
, 2017 Traballo fin de grao (UDC.CIE). Bioloxía. Curso 2016/2017[Resumen] La presencia de variantes asociadas a resistencia (VAR) en la región NS5A puede comprometer la eficacia de los antivirales de acción directa (AADs).
Gomollón Guevara, Verónica Alejandra
core
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis [PDF]
, 2020 Barclay, Stephen T. +7 more
core +3 more sources
BMC GastroenterologyBackground Sofosbuvir/Velpatasvir (Epclusa, ECS) is the first pan-genotype direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection, and Danoprevir (DNV) is the first DAA developed by a Chinese local enterprise, which is suitable for ...
Yunjing Zhou +8 more
doaj +1 more source
Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children
Pediatria PolskaSofosbuvir/velpatasvir (SOF/VEL) is a safe and effective regimen used for the treatment of chronic hepatitis C. The standard treatment duration is 12 weeks. There are no data available to support the shortened treatment.
Maria Pokorska-Śpiewak +2 more
doaj +1 more source
Аддитивные технологии: применение в медицине и фармации [PDF]
, 2019 ТЕХНОЛОГИЯ МЕДИЦИНСКАЯ /ОБОРУД /ТЕНДЕНЦИИФАРМАЦИЯ /ОБОРУД /ТЕНДЕНЦИИАДДИТИВНЫЕ ТЕХНОЛОГИИМЕТОДЫ 3D-ПЕЧАТИТЕХНОЛОГИЙ РАСПРОСТРАНЕНИЕОБЗОР ЛИТЕРАТУРЫПроведен обзор современного состояния вопроса использования аддитивных технологий в медицине и ...
Малаев, И. А. +1 more
core